Evidence map›Paper›PMID 38170256›Full record

Trial reportArchives of dermatological research2024

Topical sodium valproate-loaded nanospanlastics versus conventional topical steroid therapy in alopecia areata: a randomized controlled study.

Rania M Mogawer, Marwa Mohamed Fawzy, Ahmed Mourad, Heba Ahmed, Maha Nasr, Zeinab Ahmed Nour, Vanessa Hafez

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05017454 (Assessment of Efficacy and Safety of Sodium Valproate -Loaded Nanospanlastics in Patients With Patchy Alopecia Areata in Comparison to Conventional Therapy With Topical Steroids), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05017454 early_phase1completednot on this map

Assessment of Efficacy and Safety of Sodium Valproate -Loaded Nanospanlastics in Patients With Patchy Alopecia Areata in Comparison to Conventional Therapy With Topical Steroids: a Randomized Controlled Study, With Clinical, Dermoscopic and Molecular Asessements

TypeinterventionalSponsorKasr El Aini HospitalRan2021 to 2023Enrolled67ConditionsAlopecia AreataArmsthe optimized sodium valproate-loaded nanospanlastic dispersion, mometasone furoate lotion
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rania M MogawerDermatology Department, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt. Raniamogawer@kasralainy.edu.eg.ORCID http://orcid.org/0000-0002-9929-5413
Marwa Mohamed FawzyDermatology Department, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Ahmed MouradDermatology Department, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Heba AhmedDermatology Department, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Maha NasrPharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Zeinab Ahmed NourBiochemistry Department, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Vanessa HafezDermatology Department, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Cairo University · EGAin Shams University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA myriad of therapeutic modalities for alopecia areata are available; however, none is of high level of evidence, creating an immense need for the evaluation of other treatment modalities, of which topical sodium valproate is of potential role via proposed decrease in beta-catenin breakdown, despite its well-known side effect of hair fall as an oral therapy.

objectiveEvaluating the efficacy and the safety of sodium valproate (SV)-loaded nanospanlastics, in comparison to topical corticosteroids, this is the currently available gold standard topical treatment for patchy AA. METHODOLOGY: A total of 66 patients with patchy AA were randomly assigned to receive either topical mometasone furoate lotion or topical SV applied twice daily to all patches except a control patch, which was left untreated. Clinical, trichoscopic and biochemical assessments of beta-catenin tissue levels and Axin-2 gene expression were carried out at baseline and after 3 months.

resultsBoth therapeutic modalities were comparable. Potential efficacy was highlighted by significant improvement in the representative patch, the largest treated patch, to the control patch, the smallest untreated patch in both steroid and valproate groups (p = 0.027, 0.003 respectively). Both beta-catenin levels and Axin-2 gene expression were reduced after treatment, pointing to the inhibitory effect of dominating uncontrolled inflammatory milieu. Baseline beta-catenin was found to significantly negatively correlate with improvement in the representative patch in patients with baseline level above 0.42 ng/ml (p = - 0.042).

conclusionBoth topical SV and steroids are of comparable modest efficacy. Thus, further evaluation of SV is due in combination with intralesional steroids and other anti-inflammatory treatment modalities, together with developing individualized approaches based on baseline beta-catenin level. CLINICALTRIALS: GOV IDENTIFIER: NCT05017454, https://clinicaltrials.gov/ct2/show/NCT05017454 .

Indexed as

Alopecia AreataAxin Proteinbeta CateninHumansTreatment OutcomeValproic AcidAxin Proteinbeta CateninValproic AcidAlopecia areataBeta-cateninSodium valproateSteroids

Identifiers

PMID38170256
PMCPMC10764371
OpenAlexW4390534496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.